Our team is proud to announce that our “TRANS3” project has been selected for funding by the French National Research Agency (ANR) .
During the next 4 years (2022 – 2025 funding period), we will coordinate this exciting project entitled "TAGLN3 as a new regulator of neuroinflammation: from a biomarker to a biotarget in Alzheimer’s disease".
Thanks to this newly funded project, we are glad to have the opportunity to team up with two top partners/collaborators, Dr. Carole Escartin (Laboratoire des maladies neurodégénératives, Fontenay-aux-Roses) and Pr. Sylvain Lehmann (Laboratoire de biochimie et proteomique clinique, CHU Montpellier). We look forward to generating new and exciting data!